Cargando…
Non-steroidal anti-inflammatory drugs and clinical outcomes in patients with COVID-19
The use of non-steroidal anti-inflammatory drugs (NSAIDs) in patients with coronavirus disease 2019 (COVID-19) has raised great concerns. The effect of NSAIDs on the clinical status of COVID-19 remains in question. Therefore, we performed a post-hoc analysis from the ORCHID trial. Patients with COVI...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618688/ https://www.ncbi.nlm.nih.gov/pubmed/36325468 http://dx.doi.org/10.3389/fcimb.2022.935280 |
_version_ | 1784821106832572416 |
---|---|
author | Zhang, Jing Sheng, Hongguang Tang, Xiaoyi Xia, Panpan Li, Zhangwang Xu, Minxuan Ma, Jianyong Shen, Yunfeng Yu, Peng Liu, Xiao |
author_facet | Zhang, Jing Sheng, Hongguang Tang, Xiaoyi Xia, Panpan Li, Zhangwang Xu, Minxuan Ma, Jianyong Shen, Yunfeng Yu, Peng Liu, Xiao |
author_sort | Zhang, Jing |
collection | PubMed |
description | The use of non-steroidal anti-inflammatory drugs (NSAIDs) in patients with coronavirus disease 2019 (COVID-19) has raised great concerns. The effect of NSAIDs on the clinical status of COVID-19 remains in question. Therefore, we performed a post-hoc analysis from the ORCHID trial. Patients with COVID-19 from the ORCHID trial were categorized into two groups according to NSAID use. The 28-day mortality, hospitalized discharge, and safety outcomes with NSAIDs for patients with COVID-19 were analyzed. A total of 476 hospitalized patients with COVID-19 were included; 412 patients (86.5%) did not receive NSAIDs, while 64 patients (13.5%) took NSAIDs as regular home medication. Patients who took NSAIDs did not have a significant increase in the risk of 28-day mortality (fully adjusted: hazard ratio [HR]: 1.12, 95% CI: 0.52–2.42) in the Cox multivariate analysis. Moreover, NSAIDs did not decrease hospital discharge through 28 days (fully adjusted: HR: 1.02, 95% CI: 0.75–1.37). The results of a meta-analysis including 14 studies involving 48,788 patients with COVID-19 showed that the use of NSAIDs had a survival benefit (summary risk ratio [RR]: 0.70, 95% CI: 0.54–0.91) and decreased the risk of severe COVID-19 (summary: RR: 0.79, 95% CI: 0.71–0.88). In conclusion, the use of NSAIDs is not associated with worse clinical outcomes, including 28-day mortality or hospital discharge in American adult hospitalized patients with COVID-19. Based on current evidence, the use of NSAIDs is safe and should not be cautioned against during the COVID-19 pandemic. Ongoing trials should further assess in-hospital treatment with NSAIDs for patients with COVID-19. |
format | Online Article Text |
id | pubmed-9618688 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96186882022-11-01 Non-steroidal anti-inflammatory drugs and clinical outcomes in patients with COVID-19 Zhang, Jing Sheng, Hongguang Tang, Xiaoyi Xia, Panpan Li, Zhangwang Xu, Minxuan Ma, Jianyong Shen, Yunfeng Yu, Peng Liu, Xiao Front Cell Infect Microbiol Cellular and Infection Microbiology The use of non-steroidal anti-inflammatory drugs (NSAIDs) in patients with coronavirus disease 2019 (COVID-19) has raised great concerns. The effect of NSAIDs on the clinical status of COVID-19 remains in question. Therefore, we performed a post-hoc analysis from the ORCHID trial. Patients with COVID-19 from the ORCHID trial were categorized into two groups according to NSAID use. The 28-day mortality, hospitalized discharge, and safety outcomes with NSAIDs for patients with COVID-19 were analyzed. A total of 476 hospitalized patients with COVID-19 were included; 412 patients (86.5%) did not receive NSAIDs, while 64 patients (13.5%) took NSAIDs as regular home medication. Patients who took NSAIDs did not have a significant increase in the risk of 28-day mortality (fully adjusted: hazard ratio [HR]: 1.12, 95% CI: 0.52–2.42) in the Cox multivariate analysis. Moreover, NSAIDs did not decrease hospital discharge through 28 days (fully adjusted: HR: 1.02, 95% CI: 0.75–1.37). The results of a meta-analysis including 14 studies involving 48,788 patients with COVID-19 showed that the use of NSAIDs had a survival benefit (summary risk ratio [RR]: 0.70, 95% CI: 0.54–0.91) and decreased the risk of severe COVID-19 (summary: RR: 0.79, 95% CI: 0.71–0.88). In conclusion, the use of NSAIDs is not associated with worse clinical outcomes, including 28-day mortality or hospital discharge in American adult hospitalized patients with COVID-19. Based on current evidence, the use of NSAIDs is safe and should not be cautioned against during the COVID-19 pandemic. Ongoing trials should further assess in-hospital treatment with NSAIDs for patients with COVID-19. Frontiers Media S.A. 2022-10-17 /pmc/articles/PMC9618688/ /pubmed/36325468 http://dx.doi.org/10.3389/fcimb.2022.935280 Text en Copyright © 2022 Zhang, Sheng, Tang, Xia, Li, Xu, Ma, Shen, Yu and Liu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cellular and Infection Microbiology Zhang, Jing Sheng, Hongguang Tang, Xiaoyi Xia, Panpan Li, Zhangwang Xu, Minxuan Ma, Jianyong Shen, Yunfeng Yu, Peng Liu, Xiao Non-steroidal anti-inflammatory drugs and clinical outcomes in patients with COVID-19 |
title | Non-steroidal anti-inflammatory drugs and clinical outcomes in patients with COVID-19 |
title_full | Non-steroidal anti-inflammatory drugs and clinical outcomes in patients with COVID-19 |
title_fullStr | Non-steroidal anti-inflammatory drugs and clinical outcomes in patients with COVID-19 |
title_full_unstemmed | Non-steroidal anti-inflammatory drugs and clinical outcomes in patients with COVID-19 |
title_short | Non-steroidal anti-inflammatory drugs and clinical outcomes in patients with COVID-19 |
title_sort | non-steroidal anti-inflammatory drugs and clinical outcomes in patients with covid-19 |
topic | Cellular and Infection Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618688/ https://www.ncbi.nlm.nih.gov/pubmed/36325468 http://dx.doi.org/10.3389/fcimb.2022.935280 |
work_keys_str_mv | AT zhangjing nonsteroidalantiinflammatorydrugsandclinicaloutcomesinpatientswithcovid19 AT shenghongguang nonsteroidalantiinflammatorydrugsandclinicaloutcomesinpatientswithcovid19 AT tangxiaoyi nonsteroidalantiinflammatorydrugsandclinicaloutcomesinpatientswithcovid19 AT xiapanpan nonsteroidalantiinflammatorydrugsandclinicaloutcomesinpatientswithcovid19 AT lizhangwang nonsteroidalantiinflammatorydrugsandclinicaloutcomesinpatientswithcovid19 AT xuminxuan nonsteroidalantiinflammatorydrugsandclinicaloutcomesinpatientswithcovid19 AT majianyong nonsteroidalantiinflammatorydrugsandclinicaloutcomesinpatientswithcovid19 AT shenyunfeng nonsteroidalantiinflammatorydrugsandclinicaloutcomesinpatientswithcovid19 AT yupeng nonsteroidalantiinflammatorydrugsandclinicaloutcomesinpatientswithcovid19 AT liuxiao nonsteroidalantiinflammatorydrugsandclinicaloutcomesinpatientswithcovid19 |